Management of atrial fibrillation in COVID-19 pandemic

Yu Feng Hu; Wen Han Cheng; Yuan Hung; Wen Yu Lin; Tze Fan Chao; Jo Nan Liao; Yenn Jiang Lin; Wei Shiang Lin; Yi Jen Chen; Shih Ann Chen

doi:10.1253/circj.CJ-20-0566

Management of atrial fibrillation in COVID-19 pandemic

Yu Feng Hu
, Wen Han Cheng
, Yuan Hung
, Wen Yu Lin
, Tze Fan Chao
, Jo Nan Liao
, Yenn Jiang Lin
, Wei Shiang Lin
, Yi Jen Chen
, Shih Ann Chen

Research output: Contribution to journal › Review article › peer-review

21 Citations (Scopus)

Abstract

The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

Original language	English
Pages (from-to)	1679-1685
Number of pages	7
Journal	Circulation Journal
Volume	84
Issue number	10
DOIs	https://doi.org/10.1253/circj.CJ-20-0566
Publication status	Published - Sept 25 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Ablation
Antiarrhythmic drugs
Atrial fibrillation
Oral anticoagulation

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-20-0566

Cite this

@article{1ee209d753b34c4082fa4423fd3826a7,

title = "Management of atrial fibrillation in COVID-19 pandemic",

abstract = "The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.",

keywords = "Ablation, Antiarrhythmic drugs, Atrial fibrillation, Oral anticoagulation",

author = "Hu, \{Yu Feng\} and Cheng, \{Wen Han\} and Yuan Hung and Lin, \{Wen Yu\} and Chao, \{Tze Fan\} and Liao, \{Jo Nan\} and Lin, \{Yenn Jiang\} and Lin, \{Wei Shiang\} and Chen, \{Yi Jen\} and Chen, \{Shih Ann\}",

year = "2020",

month = sep,

day = "25",

doi = "10.1253/circj.CJ-20-0566",

language = "English",

volume = "84",

pages = "1679--1685",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "10",

}

TY - JOUR

T1 - Management of atrial fibrillation in COVID-19 pandemic

AU - Hu, Yu Feng

AU - Cheng, Wen Han

AU - Hung, Yuan

AU - Lin, Wen Yu

AU - Chao, Tze Fan

AU - Liao, Jo Nan

AU - Lin, Yenn Jiang

AU - Lin, Wei Shiang

AU - Chen, Yi Jen

AU - Chen, Shih Ann

PY - 2020/9/25

Y1 - 2020/9/25

N2 - The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

AB - The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

KW - Ablation

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Oral anticoagulation

UR - https://www.scopus.com/pages/publications/85091808965

UR - https://www.scopus.com/pages/publications/85091808965#tab=citedBy

U2 - 10.1253/circj.CJ-20-0566

DO - 10.1253/circj.CJ-20-0566

M3 - Review article

C2 - 32908073

AN - SCOPUS:85091808965

SN - 1346-9843

VL - 84

SP - 1679

EP - 1685

JO - Circulation Journal

JF - Circulation Journal

IS - 10

ER -

Management of atrial fibrillation in COVID-19 pandemic

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this